STOCK TITAN

Neuropace, Inc. - $NPCE STOCK NEWS

Welcome to our dedicated page for Neuropace news (Ticker: $NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neuropace's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neuropace's position in the market.

Rhea-AI Summary
NeuroPace, Inc. reports Q3 2023 revenue of $16.4 million, a 47% YoY increase. Full-year revenue guidance raised to $62.5-$63.5 million. Cash burn reduced to $2.2 million in Q3 2023. Gross margin improves to 74.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Summary
NeuroPace announces enhancements to its RNS System to streamline care for epilepsy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. will report Q3 2023 financial results on November 6, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Webcast and telephone access available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences earnings
Rhea-AI Summary
NeuroPace to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference on September 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
conferences
-
Rhea-AI Summary
NeuroPace reports Q2 2023 revenue of $16.5M, up 62% YoY. Full-year revenue guidance increased to $59-$61M. Cash burn reduced to $4M in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences earnings
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
Rhea-AI Summary
NeuroPace, a medical device company focused on epilepsy, has appointed Kelley Nicholas as Vice President of Sales. Nicholas brings over 15 years of experience in the medical device industry and has a track record of building high-performing teams and implementing growth-oriented strategies. NeuroPace expects Nicholas to drive the continued growth and success of its sales and commercial program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Neuropace, Inc.

Nasdaq:NPCE

NPCE Rankings

NPCE Stock Data

386.86M
10.70M
3.95%
80.9%
0.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MOUNTAIN VIEW

About NPCE

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.